Search…

CanSino Biologics (06185.HK): PCV24 initiates Phase I/II clinical trials and completes the first subject's enrollment.

26/05/2026

Zhitong Finance APP News, CanSino Biologics (06185.HK) announced that the company's 24-valent pneumococcal polysaccharide conjugate vaccine (CRM197/tetanus toxin)(PCV24) has officially initiated Phase I/II clinical trials recently, and the first subject has been enrolled.

Latest

3 m ago

Mid-finger Research Institute: Second-hand housing transactions in core cities continue to increase in May

3 m ago

Advanced packaging concepts remain active, Huatian Technology and Sanjia Technology both saw two consecutive days of gains, Yongsi Electronics rose by more than 10%, Jinfang Technology, Quick Intelligent, Tongfu Microelectric and others all opened higher.

3 m ago

Hong Kong stocks are on the move, with semiconductor stocks generally opening higher. Huawei's new technology is catalyzing the semiconductor market, and the industry is expected to embrace accelerated development opportunities.

4 m ago

Head of the Department of E-Commerce of the Ministry of Commerce introduces the development of China's e-commerce from January to April 2026.

4 m ago

The Korean won's increase expanded to 0.7%, outperforming other Asian currencies in the emerging market.

See all latest